A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
复制标题
DOI：
10.1371/journal.pone.0129865
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Zheng J
中科院分区：
文献类型：
--
作者：
Zhang Q;Zhang Y;Li K;Wang H;Li H;Zheng J
非小细胞肺癌(NSCLC)是最常见的肺癌类型，约占所有肺癌的75%-80%。吉西他滨是一种批准用于非小细胞肺癌的化疗药物。本研究的目的是开发一种新的策略，通过联合应用IRGD多肽来提高吉西他滨对非小细胞肺癌的疗效。结果表明，A549细胞株中α-v-β-3、α-v-β-5和nrp-1的阳性表达率分别为68.5%、35.3%和94.5%。伊文思蓝+IRGD组瘤内伊文思蓝蓄积量是伊文思蓝组的2.5倍。IRGD组、吉西他滨组和吉西他滨+IRGD组的抑瘤率分别为8%、59.8%和86.9%。机制研究结果显示，吉西他滨+IRGD组的增殖细胞核抗原表达较吉西他滨组降低71.5%。吉西他滨+IRGD组细胞凋亡率是吉西他滨组的2.2倍。因此，肿瘤穿透肽IRGD可以增强吉西他滨在A549移植瘤中的穿透能力和治疗效果。吉西他滨联合IRGD可能是提高吉西他滨治疗非小细胞肺癌临床疗效的新策略。
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75–80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for NSCLC by the co-administered iRGD peptide. We showed that the rates of positive expression of αvβ3, αvβ5 and NRP-1 in the A549 cell line were 68.5%, 35.3% and 94.5%, respectively. The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. The rates of growth inhibition of the tumors of the iRGD group, the Gemcitabine group and the Gemcitabine+iRGD group were 8%, 59.8% and 86.9%, respectively. The results of mechanism studies showed that PCNA expression in the Gemcitabine+iRGD group decreased 71.5% compared with that in Gemcitabine group. The rate of apoptosis in the Gemcitabine+iRGD group was 2.2 time that of the Gemcitabine group. Therefore, the tumor-penetrating Peptide iRGD can enhance the tumor-penetrating ability and therapeutic efficacy of Gemcitabine in the A549 xenograft. The combined application of Gemcitabine with iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of Gemcitabine in patients with NSCLC.
登录
查看更多内容
影响因子：
37.3
作者：
Kim MK;Jeon YK;Woo JK;Choi Y;Choi DH;Kim YH;Kim CW
通讯作者：
Kim CW
影响因子：
8.8
作者：
Akashi, Y.;Oda, T.;Ohara, Y.;Miyamoto, R.;Kurokawa, T.;Hashimoto, S.;Enomoto, T.;Yamada, K.;Satake, M.;Ohkohchi, N.
通讯作者：
Ohkohchi, N.
DOI：
10.1016/j.lungcan.2013.09.012
发表时间：
2013-12
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
--
作者：
Aizawa K;Liu C;Veeramachaneni S;Hu KQ;Smith DE;Wang XD
通讯作者：
Wang XD
影响因子：
10.3
作者：
Gridelli, C;Perrone, F;Gebbia, V
通讯作者：
Gebbia, V
影响因子：
5.3
作者：
Gridelli, Cesare;De Maio, Ermelinda;Perrone, Francesco
通讯作者：
Perrone, Francesco